title: [Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate].
abstract: The effect of pretreatment with bismuth subnitrate (BSN) for prevention of the renal toxicity of cisplatin (CDDP) was examined in 44 patients with lung cancer (43 non-small cell and one small cell lung cancer). In non-small cell lung cancer cases, the effect of the antitumor activity of chemotherapeutic drugs was observed in 62% of patients pretreated with BSN, and 42% in the group without pretreatment with BSN. No antitumoral activity of chemotherapeutic drugs was suppressed by treatment with BSN. In the group without pretreatment of BSN, serum creatinine and BUN were in proportion to the number of administrations of chemotherapeutic drugs. On the other hand, no renal toxicity was shown in the group with pretreatment by BSN. No protective effect against myelosuppression with pretreatment by BSN was demonstrated, perhaps because of the influence of anti-cancer drugs apart from CDDP.
authors.affiliation: Dept. of Internal Medicine, Matsudo National Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Hamada
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiwaki
authors.forename: T
authors.initials: T
authors.lastname: Kodama
authors.forename: A
authors.initials: A
authors.lastname: Hayashibe
authors.forename: N
authors.initials: N
authors.lastname: Nukariya
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Morikawa
authors.forename: T
authors.initials: T
authors.lastname: Hirosawa
authors.forename: T
authors.initials: T
authors.lastname: Matsuyama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: C010804:bismuth subnitrate; D002945:Cisplatin; D001729:Bismuth